Last reviewed · How we verify
Vehicle (base cream)
Vehicle (base cream) is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development.
This drug serves as a base cream for vehicle purposes.
Vehicle, a base cream, has been used as a control in clinical trials for various skin conditions, including Atopic Dermatitis, Cutaneous Leishmaniasis, Diabetic Foot Ulcer, and Cutaneous Warts. The exact mechanism of action of Vehicle is unknown, as it is classified as a base cream with no specific modality.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
GlaxoSmithKline is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vehicle (base cream) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The base cream is used as a vehicle for other topical medications, providing a delivery system for active ingredients.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (PHASE3)
- Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin (NA)
- Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients (PHASE2, PHASE3)
- Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) (PHASE3)
- Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers (PHASE2, PHASE3)
- A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD) (PHASE1)
- Jaktinib Hydrochloride Cream For Atopic Dermatitis (PHASE1, PHASE2)
- Comparison of LimpiAD Cream 2.5% Plus Versus Its Vehicle and and a Basic Emollient in Patients With Atopic Dermatitis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vehicle (base cream) CI brief — competitive landscape report
- Vehicle (base cream) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Vehicle (base cream)
What is Vehicle (base cream)?
How does Vehicle (base cream) work?
Who makes Vehicle (base cream)?
What development phase is Vehicle (base cream) in?
Related
- Manufacturer: GlaxoSmithKline — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing